Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC
Advances in Therapy · 2024
DOI: 10.1007/s12325-024-02899-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Therapy, 2024. Verfasst von Konstantinos Arnaoutakis und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Arkansas for Medical Sciences, Little Rock, AR, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Anaplastic Lymphoma Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
INTRODUCTION: Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are standard first- and second-line treatment for advanced ALK+ non-small cell lung cancer (NSCLC). We evaluated outcomes in patients with ALK+ NSCLC receiving third-line ALK TKI versus non-ALK-directed therapy. METHODS: Flatiron Health OncoEMR data were extracted for patients with ALK+ NSCLC initiating first-line ALK TKI between January 2015 and March 2022 followed by second-line ALK TKI and third-line ALK TKI (group A) or non-TKI therapy (group B). Time-to-treatment discontinuation (TTD) and overall survival (OS) were analyzed using multivariate modelling. RESULTS: Among patients receiving third-line ALK TKI (A, n = 85) or non-TKI therapy (B, n = 43), most received first-line crizotinib (A/B: 64%/60%) and second-line alectinib (36%/30%), ceritinib (24%/19%), or lorlatinib (15%/30%). Common third-line treatments were lorlatinib/alectinib (41%/33%) in A and immunotherapy, chemotherapy, or chemotherapy + immunotherapy (30%/28%/21%) in B. Group A versus B had longer TTD of first-line treatment (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.41-0.93; p = 0.020) and second-line treatment (HR 0.50, 95% CI 0.33-0.75; p < 0.001) and longer OS from start of first-line treatment (HR 0.32, 95% CI 0.19-0.54; p < 0.001) and second-line treatment (HR 0.40, 95% CI 0.24-0.66; p < 0.001). For third-line treatment, median TTD (A/B) was 6.2/2.4 months (HR 0.61, 95% CI 0.37-1.00; p = 0.049) and OS was 17.6/6.5 months (HR 0.57, 95% CI 0.33-0.98; p = 0.042). CONCLUSIONS: Patients receiving third-line non-ALK-directed therapy had suboptimal outcomes on prior TKIs. Patients with longer duration of prior ALK TKI treatment appeared to benefit from third-line ALK TKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA, 02142, USA.
- Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA.
- Takeda Pharmaceuticals America, Inc., Lexington, MA, USA.
- Mayo Clinic, Rochester, MN, USA.
- Global Evidence and Outcomes Research, Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA, 02142, USA. mark.lin@takeda.com.
Zitieren
APA
Arnaoutakis, K., Wan, Y., Elliott, J., Young, M., Yin, Y., Leventakos, K., Lin, H. M., & Dimou, A. (2024). Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. Advances in Therapy. https://doi.org/10.1007/s12325-024-02899-6
Vancouver
Arnaoutakis K, Wan Y, Elliott J, Young M, Yin Y, Leventakos K, et al. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. Advances in Therapy. 2024. doi:10.1007/s12325-024-02899-6
BibTeX
@article{Arnaoutakis2024,
author = {Arnaoutakis, Konstantinos and Wan, Yin and Elliott, Jennifer and Young, Matt and Yin, Yu and Leventakos, Konstantinos and Lin, Huamao M and Dimou, Anastasios},
title = {Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC},
journal = {Advances in Therapy},
year = {2024},
doi = {10.1007/s12325-024-02899-6}
}
EUVIMED